Loading news...
NVCR gains Japan NHI reimbursement for Optune Lua in advanced NSCLC, expanding patient access and supporting adoption of its TTFields cancer therapy platform.
Explore NovoCure's (NVCR) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country's National Health Insurance coverage. Optune Lua is approved in Japan for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy. “Lung cancer remains one of the leading causes of cancer deaths in Japan. Healt.
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2026 Leerink Global Healthcare Conference.
NovoCure (NVCR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.61 per share a year ago.
NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult patients with newly diagnosed glioblastoma. British Columbia is the first province to provide coverage following Canada's Drug Agency's assessment and reimbursement recommendation for TTFields therapy in glioblastoma. “Glioblastoma is one of the most aggressive cancers, and treatment options.
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
NVCR wins early FDA nod for Optune Pax in pancreatic cancer, boosting survival in phase III and opening TTFields-driven market.
Weekly Market HighlightsWeekly breadth was slightly negative with 4,703 advancers versus 4,832 decliners, even as 963 stocks gained more than 10% and 1,151 fel
NovoCure secures FDA approval for Optune Pax in first-line locally advanced pancreatic cancer, the first such approval in three decades. The company is positioned for further expansion with the phase 2 PANOVA-4 trial in 1st-line metastatic pancreatic cancer; topline data is expected in Q1 2026. Full-year 2025 revenues grew 8% year-over-year to $655.4 million, supported by 4,620 active TTFields patients globally and strong U.S. sales momentum.
Stocks were poised for a higher open Thursday, a day after major equities indexes ticked lower, with the Dow Jones Industrial Average snapping a three-session winning streak during which it set intraday and closing records each day.
Novocure stock surged after the Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain pancreatic cancers.
U.S. stock futures rose on Thursday following Wednesday's decline. Futures of major benchmark indices were higher after the strong January jobs report.
NovoCure stock (NVCR) is up over 30% following the FDA's approval of its Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment in almost 30 years.
NovoCure shares surged after FDA approval of Optune Pax for locally advanced pancreatic cancer.
The Swiss biopharmaceutical company's shares surged in after-hours trading after it said the FDA approved its Optune Pax product.